Cargando…

Sodium Levels and Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving Nivolumab

IMPORTANCE: Low sodium levels have been associated with negative outcomes among patients with metastatic renal cell carcinoma (mRCC) receiving therapies other than immune checkpoint inhibitors (ICIs). OBJECTIVE: To investigate the role of natremia in patients with mRCC receiving nivolumab as a secon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Catalano, Martina, Rebuzzi, Sara Elena, Maruzzo, Marco, De Giorgi, Ugo, Buti, Sebastiano, Galli, Luca, Fornarini, Giuseppe, Zucali, Paolo Andrea, Procopio, Giuseppe, Chiellino, Silvia, Milella, Michele, Catalano, Fabio, Pipitone, Stefania, Ricotta, Riccardo, Sorarù, Mariella, Mollica, Veronica, Tudini, Marianna, Fratino, Lucia, Prati, Veronica, Caffo, Orazio, Atzori, Francesco, Morelli, Franco, Prati, Giuseppe, Nolè, Franco, Vignani, Francesca, Cavo, Alessia, Di Napoli, Marilena, Malgeri, Andrea, Naglieri, Emanuele, Signori, Alessio, Banna, Giuseppe Luigi, Rescigno, Pasquale, Antonuzzo, Lorenzo, Roviello, Giandomenico
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2023
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10682835/ https://www.ncbi.nlm.nih.gov/pubmed/38010650 http://dx.doi.org/10.1001/jamanetworkopen.2023.45185

Ejemplares similares

The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study
por: Rebuzzi, Sara Elena, et al.
Publicado: (2022)

The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The Δ-Meet-URO analysis
por: Rebuzzi, Sara Elena, et al.
Publicado: (2022)

Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study)
por: Rebuzzi, Sara Elena, et al.
Publicado: (2021)

Impact of Previous Nephrectomy on Clinical Outcome of Metastatic Renal Carcinoma Treated With Immune-Oncology: A Real-World Study on Behalf of Meet-URO Group (MeetUro-7b)
por: Stellato, Marco, et al.
Publicado: (2021)

Characterization of Tumor and Immune Tumor Microenvironment of Primary Tumors and Metastatic Sites in Advanced Renal Cell Carcinoma Patients Based on Response to Nivolumab Immunotherapy: Preliminary Results from the Meet-URO 18 Study
por: Rebuzzi, Sara Elena, et al.
Publicado: (2023)

The Geriatric G8 Score Is Associated with Survival Outcomes in Older Patients with Advanced Prostate Cancer in the ADHERE Prospective Study of the Meet-URO Network
por: Banna, Giuseppe Luigi, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives
por: Rebuzzi, Sara Elena, et al.
Publicado: (2022)

Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
por: Catalano, Martina, et al.
Publicado: (2022)

Adherence to Oral Treatments in Older Patients with Advanced Prostate Cancer, the ADHERE Study: A Prospective Trial of the Meet-URO Network
por: Rescigno, Pasquale, et al.
Publicado: (2022)

Incidence and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with metastatic castration-resistant prostate cancer
por: Caffo, Orazio, et al.
Publicado: (2020)

Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib
por: Rebuzzi, Sara Elena, et al.
Publicado: (2022)

Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study
por: Basso, Umberto, et al.
Publicado: (2022)

Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysis
por: Anpalakhan, Shobana, et al.
Publicado: (2023)

Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a)
por: Stellato, Marco, et al.
Publicado: (2023)

Prognostic value of normal sodium levels in patients with metastatic renal cell carcinoma receiving tyrosine kinase inhibitors
por: Roviello, Giandomenico, et al.
Publicado: (2022)

Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program
por: Rebuzzi, S.E., et al.
Publicado: (2022)

Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet‐Uro 19BEYOND study
por: Roviello, Giandomenico, et al.
Publicado: (2022)

Liquid biopsy in colorectal cancer: No longer young, but not yet old
por: Roviello, Giandomenico, et al.
Publicado: (2022)

First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series
por: Buti, Sebastiano, et al.
Publicado: (2021)

Very high-risk prostate cancer: multimodality treatment will be the new frontier
por: Campobasso, Davide, et al.
Publicado: (2017)

Association between Low-Grade Chemotherapy-Induced Peripheral Neuropathy (CINP) and Survival in Patients with Metastatic Adenocarcinoma of the Pancreas
por: Catalano, Martina, et al.
Publicado: (2021)

The impact of age, performance status and comorbidities on nab-paclitaxel plus gemcitabine effectiveness in patients with metastatic pancreatic cancer
por: Catalano, Martina, et al.
Publicado: (2022)

Turning losses into gain in nonlinear optics
por: Prati, Franco
Publicado: (2018)

Present and future of coronary risk assessment
por: Prati, Francesco, et al.
Publicado: (2021)

Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort
por: Fornarini, G., et al.
Publicado: (2021)

The Prognostic Role of Baseline Metabolic Tumor Burden and Systemic Inflammation Biomarkers in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223: A Proof of Concept Study
por: Bauckneht, Matteo, et al.
Publicado: (2020)

On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2
por: Caffo, O., et al.
Publicado: (2020)

GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreak
por: Bersanelli, Melissa, et al.
Publicado: (2021)

Prognostic and Predictive Factors in Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors: A Review of the Current Evidence
por: Rebuzzi, Sara Elena, et al.
Publicado: (2021)

Post combustion CO(2) capture with calcium and lithium hydroxide
por: Costagliola, Maria Antonietta, et al.
Publicado: (2022)

The risk of acute coronary events in microvascular disease
por: Varrichione, Giuseppe, et al.
Publicado: (2022)

Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy
por: Munzone, Elisabetta, et al.
Publicado: (2006)

Correction: Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy
por: Munzone, Elisabetta, et al.
Publicado: (2006)

Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study)
por: Bersanelli, Melissa, et al.
Publicado: (2021)

Correlation Between Tumor Response and Survival Outcomes in Patients with Advanced Gastric Cancer Receiving Ramucirumab and Paclitaxel as Second-Line Therapy
por: Roviello, Giandomenico, et al.
Publicado: (2022)

Concomitant Drugs Prognostic Score in Patients With Metastatic Renal Cell Carcinoma Receiving Ipilimumab and Nivolumab in the Compassionate Use Program in Italy: Brief Communication
por: Buti, Sebastiano, et al.
Publicado: (2023)

Editorial: Microbiota and metabolites in cancer immunotherapy
por: Roviello, Giandomenico, et al.
Publicado: (2022)

Nonlinear optical systems
por: Lugiato, Luigi, et al.
Publicado: (2015)

The role of mean corpuscular volume and red cell distribution width in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: the MARECAP retrospective study
por: Tommasi, Chiara, et al.
Publicado: (2023)

Beyond BRCA: The Emerging Significance of DNA Damage Response and Personalized Treatment in Pancreatic and Prostate Cancer Patients
por: Dalmasso, Bruna, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jpbq4fkmer9kktds1ivm1ssblt